Identify ZINFORO^® Patient With CAP

How do you identify your ZINFORO^® patients with CAP?^1-4,*

Profiles of ZINFORO^® patients with CAP^5,6,*

Patient 1: Elderly patient with CAP having structural lung disease

A 70-year-old male with structural lung disease presents with dyspnoea, fever with chills and cough.

Patient presentation, history and risk factors

• History of structural lung disease
   
• Shortness of breath/Laboured breathing (dyspnoea)
   
• RR, 33 breaths/minute
   
• PORT Score IV (severe respiratory infection)
   
• Fever with chills and cough
   
• History of smoking
   
• Recent alcoholism
   
• Hospitalisation for prior pneumonia 4 months ago
   
• Nursing home resident

Patient 2: Patient with CAP having renal insufficiency

A 56-year-old female presents with rapidly progressing CAP.^†

Patient presentation, history and risk factors

• Rapidly progressing CAP
   
• Rapidly deteriorating; may require ICU in the next 24 hours
   
• Severe renal insufficiency (CrCl at hospital admission: 23 mL/min)
   
• CrCl falling rapidly
   
• History of asthma
   
• History of prior antibiotic use

Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which ZINFORO^® could be considered.

^*There is no experience with ZINFORO® in the treatment of CAP in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock and severe underlying lung disease, those with PORT risk Class V, and/or CAP requiring ventilation at presentation, CAP due to MRSA and patients requiring intensive care. The available clinical data cannot substantiate efficacy against PNSP.^1
†ZINFORO^® is primarily excreted by the kidneys and the dose should be reduced in patients with moderate-to-severe renal insufficiency.¹

​​​​​​​CAP, community-acquired pneumonia; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin-non–susceptible pneumococci; PORT, Pneumonia Patient Outcomes Research Team; RR, respiratory rate.
​​​​​​​

References: